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The complexity of standard medical treatment for heart failure is growing, and such therapy typically in-
volves 5 or more different medications. Given these pressures, there is increasing interest in harnessing
cardiovascular biomarkers for clinical application to more effectively guide diagnosis, risk stratification,
and therapy. It may be possible to realize an era of personalized medicine for heart failure treatment in
which therapy is optimized and costs are controlled. The direct mechanistic coupling of biologic processes
and therapies achieved in cancer treatment remains elusive in heart failure. Recent clinical trials and meta-
analyses of biomarkers in heart failure have produced conflicting evidence. In this article, which com-
prises a summary of discussions from the Global Cardiovascular Clinical Trialists Forum held in Paris,
France, we offer a brief overview of the background and rationale for biomarker testing in heart failure,
describe opportunities and challenges from a regulatory perspective, and summarize current positions
from government agencies in the United States and European Union. (J Cardiac Fail 2013;19:592e599)
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592oncology, biomarker testing is used to identify treatments
for highly specific molecular targets to match effective ther-
apies to specific populations, thereby improving tolerance
to treatments with toxicity profiles that would be unaccept-
able in an unselected population.1e3 The clinical utility of
biomarkers in the arena of cardiology is less clear, due in
part to the fact that usual practice groups together several
pathways leading to heart failure (HF) as well as the corre-
sponding selection of therapies.
In addition, the heterogeneity of HF compared with
a given type of cancer adds a complicating factor. Oncotype
diagnostic assays use multimarker profiling to assess thera-
peutic options in oncology. Most of these profile somatic al-
terations (eg, estrogen receptor or HERG2 status in tumor
cells) that are usually related to tumor cell mutations. In
cardiology, however, genetic variants likely to influence
therapeutic decisions are typically germline and as such
only indirectly modify disease prognosis or response to
therapy. Historical and biologic factors affecting the focus
of research to date may also explain the relatively more
thorough investigation of biomarkers in oncology. For in-
stance, estrogen receptor status in breast cancer directly
Biomarker-Guided Therapies in Heart Failure  Fiuzat et al 593
dictates treatment with tamoxifen, thus mechanistically
linking the marker to a biologic process and treatment4da
success that has not yet been achieved in HF.
However, there are numerous reasons for exploring
the use of biomarkers to guide therapy in HF, including
challenges in optimizing therapy and utility for risk stratifi-
cation and prognosis.5 In the present article, which includes
a summary of discussions from the Global Cardiovascular
Clinical Trialists Forum in Paris, France, we provide a brief
overview of current evidence regarding biomarker-guided
therapy and diagnosis and elucidate some of the challenges,
opportunities, and rationales for future research in
biomarker-guided therapy in HF. We focus primarily on
circulating biomarkers and pharmacogenetics. Finally, we
survey the current regulatory framework in this arena.
Rationales for the Use of Biomarkers in Heart
Failure
Approximately 5.1 million people $20 years old in the
USA live with chronic HF. An estimated 670,000 new cases
are diagnosed annually among USA adults $45 years old,
and HF causes or contributes to almost 300,000 deaths each
year.6 Various demographic trends, including the aging of
the population and greater likelihood of survival after acute
myocardial infarction, suggest that the prevalence of HF
will likely continue to increase; indeed, the American Heart
Association estimates that by 2030, HF prevalence will in-
crease by 25% over 2013 estimates.6 Although there have
been significant advances in the treatment of HF, morbidity
and mortality remain high. Pharmacologic regimens have
become increasingly complex, and standard therapy now
often consists of multiple drugs (angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, beta-
blockers, aldosterone antagonists, diuretics, digoxin, and,
in African-American patients, hydralazineeisosorbide dini-
trate). The economic impact is significant as well: Costs of
HF hospitalizations amount to w$29 billion/year in the
USA alone.6
Heterogeneity in response to therapies warrants further
research to identify biomarkers that can not only stratify
risk but also identify the underlying disease process that
may be targeted by specific therapies. Recognizing the het-
erogeneity of HF and dissecting it into different therapeutic
groups would improve the targeting of interventions, which
in turn could improve response rates and avoid adverse ef-
fects in patients unlikely to benefit. Studies have demon-
strated the need to target specific phenotypes based on
this heterogeneity.7 Better, more precise targeting of thera-
pies could allow the focused use of those drugs most likely
to be effective and safe in a given individual, thereby poten-
tially enhancing compliance, improving outcomes, and
lowering the cost of medical care.
Several small studies and a recent meta-analysis suggest
better clinical outcomes with a biomarker-guided approach
using natriuretic peptides.8 However, recent European Soci-
ety of Cardiology (ESC)9 and American Heart Association/American College of Cardiology guidelines10 for HF con-
clude that there is insufficient evidence to recommend
biomarker-guided therapy in the management of HF pa-
tients. Therefore, in contrast to oncology, biomarker ap-
proaches are not yet routinely used in the management of
HF.
Overview of Biomarker-Guided Approaches in
Heart Failure
Biomarker testing in HF has typically sought to identify
patients who may be being treated in suboptimal fashion
rather than those who need a specific drug or device ther-
apy. There are essentially 4 different kinds of biomarkers:
prognostic, predictive, theranostic, and surrogate, as de-
scribed in Table 1. A distinction between prognostic and
predictive markers is worth noting: A marker is considered
to be predictive if it shows differential benefit of a particular
therapy based on marker status (eg, only patients with
a given marker will respond well to a specific therapy);
prognostic markers provide information about an outcome
in the absence of therapy or portend an outcome different
from that experienced by patients without the marker, re-
gardless of therapy.11e13 Prognostic markers, therefore,
are affected similarly under treatment: the higher (or lower)
the marker, the better the outcome regardless of treatment;
such markers may be used for risk stratification. Theranos-
tic markers, which modify treatment effect in terms of rel-
ative risk, include a range of approaches, such as
pretreatment identification of patient subgroups likely to re-
spond to therapy or at higher risk of drug side effects, or
monitoring of drug efficacy and safety once treatment be-
gins. Predictive markers, however, have a significant inter-
action with a specific treatment. For example, those with
high values of a predictive marker may have a better out-
come with treatment than those with low values.
Statistical Considerations: Effect Models
An effect model describes the relationship between the
risk with treatment (Rt) as a function ( f ) of the risk without
treatment (Rc, for the risk in the control group of a random-
ized trial): Rt 5 f(Rc). Prognostic markers modify the posi-
tion of the patients on the untreated risk axis (Rc), whereas
theranostic markers alter the prediction of treated risk (Rt)
through the f function (Fig. 1).14 Building the complete ef-
fect model through the identification of relevant biomarkers
and their role is an essential step toward the practice of per-
sonalized medicine. Cox and logistic models are examples
that can be used for this purpose.
The reduction of risks of stroke and myocardial infarc-
tion by aspirin therapy in the context of primary prevention
illustrates the modification of the effect model according to
sex.15 Myocardial infarction is reduced in men (relative risk
[RR] 0.68, 95% confidence interval [CI] 0.54e0.86) but not
in women (RR 0.99, 95% CI 0.83e1.19). Risk of stroke,
however, is reduced in women (RR 0.81, 95% CI
0.69e0.96) but increased in men (RR 1.13, 95% CI
Table 1. Biomarker Types
Type Description Examples in Cardiovascular Disease
Prognostic markers Measure increased risk of events Age
Natriuretic peptides
LVEF
Troponin
Gal-3
ST2
GDF-15
HDL/LDL cholesterol
QSOX1
Predictive markers Used to make treatment decisions VKORC1 (warfarin)
CYP2C9 (warfarin)
CYP2C19 (clopidogrel)
QRS duration (ICDs)
Theranostic markers Modify treatment effect in terms of relative risk LVEF (preserved vs reduced)
Heart rate (ivabradine)
LBBB (CRT)
Surrogate markers Part of the mechanism of action of the treatment, and
where utility resides in guiding therapy during follow-up
Blood pressure
LDL cholesterol
Serum creatinine
Hemoglobin A1c
CYP2C9, Cytochrome P450 2C9; CYP2C19, Cytochrome P450 2C19; Gal-3, galectin-3; GDF-15, growth differentiation factor-15; HDL, high-density
lipoprotein; ICD, implantable cardioverter/defibrillator; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; QSOX1, quiescin-Q6.
594 Journal of Cardiac Failure Vol. 19 No. 8 August 20130.96e1.33). Thus, sex plays the role of theranostic marker
for the benefit of aspirin, depending on the outcome
considered.
Pharmacogenetics in Heart Failure
Beta-blockers are a cornerstone of chronic HF therapy.16
However, they may be poorly tolerated or less effective in
some patients, making this a logical possibility for a genet-
ically guided approach. The b1-adrenergic receptor (AR)
position 389 Arg/Gly polymorphism has been widely ex-
amined. Most studies have been small and characterized
by a number of limitations, and they have reported conflict-
ing results regarding effects on disease risk, disease pro-
gression, and response to treatment.17e21
Two large phase III randomized trials of beta-blockers in
HFdthe Metoprolol CR/XL Randomized Intervention
Trial in Heart Failure (MERIT-HF)22 and the Beta-
Blocker Evaluation of Survival Trial (BEST)18dincluded
DNA substudies that examined this polymorphism. In
MERIT-HF, no effect of the polymorphism was observedFig. 1. Among possible models, the multiplicative effect model (EM) assu
stant whatever the baseline risk; the ‘‘f’’ function is the multiplication by Ron the combined end point of time to all-cause mortality
or HF hospitalization in either the placebo or the metopro-
lol succinate groups. In contrast, BEST showed a substantial
effect of the polymorphism on response to treatment with
bucindolol, likely owing to a pharmacologic interaction
with the effects of bucindolol, with no effect on HF or ar-
rhythmia end points observed in the placebo group.18
More recent studies have shown no difference in out-
comes by genotype in patients treated with metoprolol or
carvedilol.21 The basis for the apparent interaction of the
b1 389 Arg/Gly polymorphism with bucindolol, which is
not found with carvedilol or metoprolol, likely resides in
the unique pharmacologic properties of bucindolol,16e18
but further studies are needed to elucidate this issue.
Polymorphisms in the renin-angiotensin-aldosterone sys-
tem (RAAS) have also been examined,23,24 and explora-
tions aimed at identifying treatment selection and dosing
with these genetic variations are in process.25e27
Other areas of nonpharmacologic investigation include
pharmacogenetic associations with response to exercise,28mes that relative risk (RR 5 Rt/Rc) associated with treatment is con-
R; theranostic markers (TMs) may be associated with different RR.14
Fig. 2. Forest plot of all-cause mortality among patients with heart
failure randomized to biomarker-guided therapy versus control.
Reprinted from Am Heart J, 158, Felker GM, Hasselblad V, Her-
nandez AF, O’Connor CM, Biomarker guided therapy in chronic
heart failure: a meta-analysis of randomized controlled trials,
422-30, 2009, with permission from Elsevier.
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as well as implantable cardiac defibrillators29 and biventric-
ular pacing in HF. However, the clinical utility of pharma-
cogenetic testing in cardiovascular patients remains
challenging, as demonstrated by antiplatelet agents.30 Fun-
damental questions remain about genotyping and the utility
in modifying antiplatelet therapy on the basis of such
testing.31
Research efforts are currently evaluating many other
potential pharmacogenetic targets, including the a2c-adren-
ergic receptor,32 endothelial nitric oxide synthase,33
G-protein b3 subunit,34 acetylcholine receptor M2 gene,35
G-proteinecoupled receptor kinase variants,36 and Corin
polymorphisms.37 Although research is progressing rapidly,
further studies are necessary to establish genetic testing for
targeting efficacy or safety with HF therapies.
Natriuretic Peptides
Among the available biomarkers in HF, natriuretic
peptides (NPs) (both B-type NP [BNP] and the amino-
terminal [NT-proBNP]) have accumulated the most evi-
dence linking them to outcomes, although their optimal
clinical application remains uncertain. Studies show that
NT-proBNP levels on hospital admission predict long-
term mortality and that patients whose NP levels decrease
during acute hospitalization have a better prognosis than
those whose levels do not change.38
Following a small pilot study published in 2000,39 a series
of randomized trials, all of them relatively small and most
single-blinded, examined the use of NP-guided therapy in
patients with HF. They included the STARS-BNP,40
TIME-CHF,41 SIGNAL HF,42 and PRIMA trials43; the Vien-
na study44; the BATTLESCARRED,45 PROTECT,46 UP-
STEP,47 and STARBRITE48 studies; and a small (n 5 60)
trial by Anguita et al.49 Primary results from these studies
were published from 2007 to 2011. With the exceptions of
SIGNAL HF and Anguita et al, the study comparisons
showed an advantage for BNP-guided therapy over the
comparator arm. In addition, the 2009 meta-analysis by
Felker et al,8 which focused on findings reported from the
Troughton et al,39 STARBRITE, STARS-BNP, BATTLE-
SCARRED, TIME-CHF, and PRIMA studies, found that
the use of NP measurements as a guide for the titration of
therapy in HF was associated with a w30% reduction in
mortality.8 However, the confidence intervals for the hazard
ratios reported in the meta-analysis were in some cases
wide, and most crossed the line of no effect (Fig. 2).8
As Felker et al noted, a clear indication for the role
of NP-guided therapy in HF still awaits definitive elucida-
tion in an adequately powered randomized trial.8 One
such study is currently under way: the Guiding Evidence-
Based Therapy Using Biomarker-Intensified Treatment
(GUIDE-IT) randomized trial (ClinicalTrials.gov identifier
NCT01685840), which opened to patient enrollment
in December 2012 and is expected to include w1,100
participants. In addition, midregional proeA-type NP
(MR-proANP) has recently emerged as a biomarker with
prognostic potential in early trials.50Other Biomarkers in Heart Failure
A number of other biomarkers have been associated with
an increased risk of poor outcomes in patients with HF, in-
cluding ST2, galectin-3, growth differentiation factor-15, c-
reactive protein, neutrophil gelatinase-associated lipocalin,
copeptin, malondialdehyde, and others,51e59 but none has
an established indication for risk stratification in current
HF guidelines. More recently, mass spectrometry assays ap-
plied to protein-based biomarker discovery have yielded
a new potential diagnostic biomarker for acute decompen-
sated HF: the quiescin-Q6 (QSOX1) protein.60 Some stud-
ies have shown that some of these biomarkers might be
used to guide therapy, although no prospective studies
have been performed to test this strategy.61e64
In recent years, it has become evident that alterations in
gene and protein expression underlie the disease process
and determine its progression as well as outcomes. The
use of ‘‘omics’’-based biomarker approaches offers the op-
portunity to predict the disease phenotype, develop com-
panion diagnostics, and make specific treatment decisions.
In HF, several omics-based biomarkers have been identified
and show promise for patient stratification and guided ther-
apy. These include genomics, transcriptional profiling (es-
pecially microRNAomics), proteomics, and metabolomics.
Rather than a single approach, the integration of genomic,
proteomic, and patient characteristics (phenotype) into
a single model may be the first step toward better models
for predicting response to therapy and outcomes, ie, ‘‘per-
sonalized medicine.’’
Better biomarkers are urgently needed to improve
screening, diagnosis, and monitoring of diseases; for guid-
ing molecularly targeted therapy; and for monitoring thera-
peutic response, especially in syndromes such as HF that
are clinically and pathophysiologically heterogeneous and
frequently associated with multiple comorbid conditions.
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Issues to Consider
There are a number of issues to consider when interpret-
ing the data. The first is the concept of regression to the
mean, which is evident in biomarker-guided investigations
in which the largest studies have been neutral or negative.
However, results from a meta-analysis of biomarker-
guided therapies in HF still indicated an overall benefit.8
These contradictory findingsdwhich may themselves pos-
sibly arise from a variety of causes, including publication
and/or reporting biasdhighlight the unmet need for a ro-
bustly powered study that can definitively determine
whether guiding therapy based on serial measurement of
NPs improves outcomes in HF.
Second, it has been suggested that younger patients in
these trials may experience greater benefit than older pa-
tients,41,65 further underscoring the need for evaluation in
a large sufficiently powered trial. Critics of biomarker-
guided approaches argue that providers should titrate drugs
and use evidence-based therapies regardless of BNP values.
Although data suggest that there is room for improvement
in maximizing evidence-based therapies,66,67 a growing
body of evidence supports biomarkers as surrogates, though
this remains to be validated.
Finally, there is concern that the results have been unpre-
dictable.68,69 One possible explanation might be that in
biomarker-guided studies, it is assumed that the patients
with the highest levels of a biomarker are likely to benefit
more than those with lower levels. Several studies suggest
that this might not be true, and that in fact those with higher
biomarker levels could be too sick to benefit from therapy
and those with lower levels are more able to benefit.68 There-
fore, developing biomarker-guided therapies requires careful
consideration of what patients to target, whether the target
goals are correct (using absolute values versus percentage re-
ductions), and a number of issues relating to trial design.
In addition, challenges exist surrounding the validation of
biomarkers for use in clinical practice, including: discrimina-
tion (the ability to separate low- and high-risk individuals)
and calibration (the ability to accurately predict the level of
risk) for a prognostic marker; reproducibility of the interac-
tion between treatment effect and level of a predictivemarker
(are the ratios between hazard ratios, odds ratios, or relative
risks in the presence or absence of the biomarker reproduc-
ible between studies?); and prediction (does the level of sur-
rogate on treatment predict the clinical benefit?) and captureTable 2. Phases of Evaluation
1. Proof of concept: Do novel marker levels differ between subjects with and w
2. Prospective validation: Does the novel marker predict development of future
3. Incremental value: Does the novel marker add predictive information to estab
4. Clinical utility: Does the novel risk marker change predicted risk sufficiently
5. Clinical outcomes: Does use of the novel risk marker improve clinical outcom
6. Cost-effectiveness: Does use of the marker improve clinical outcomes sufficie
Reproduced with permission from Hlatky et al.70 Reprinted from Circulation, 119
MS, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scien
permission from Wolters Kluwer Health.(does the level of surrogate on treatment explain the observed
clinical benefit?) as essential properties for surrogate
markers. Table 2 summarizes a series of key steps in validat-
ing candidate biomarkers for use in clinical practice.70
Approvability of Biomarker-Guided Therapy
A number of regulatory issues must be considered in the
context of studies of biomarker-guided therapy. In particu-
lar, the generalizability of the findings is of critical impor-
tance. What were the inclusion and exclusion criteria of the
population studied? Are there cultural patterns to care that
preclude the use of biomarkers?
Other key issues are the risk of treatment and the need to
adjust doses. This is relevant when the treatment involves
exposure-based dosing, where there is an expectation of
a link between exposure and outcome. For example, there
is no utility in testing renin levels to adjust or administer
RAAS inhibitors. Why consider testing when patients
should be treated anyway? To return to our contrasting ex-
ample of oncology, in the arena of cancer therapy, decisions
largely depend on a risk-benefit balance for choosing treat-
ment options. Because agents are typically highly toxic,
such an approach becomes valuable in the decision matrix.
In cardiology, treatments are generally safer, and the weight
of evidence supports the risk-benefit ratio in favor of bene-
fit. Additionally, biomarkers most commonly used in oncol-
ogy are products of the primary cause of the disease (ie,
tumor cells), rather than indirect downstream modulators
as is typically the case with cardiovascular markers.
Finally, safety issues should be addressed. First, can the
marker allow risk to be avoided? Or, in other words, can it
identify patients in whom the treatment should not be used
or identify who should titrate to higher doses or those who
may be more sensitive? Second, when guiding therapy
with markers, is there a risk that aggressive adjustment of in-
dicated therapies may cause harm? Furthermore, the ability
to select optimal therapeutic agents for a given patients could
improve adherence to medication and expose patients to
smaller numbers of drugs. A number of new trials and initia-
tives will provide important information on these questions.
Funding Opportunities: United States and
European Union
The National Heart, Lung, and Blood Institute (NHLBI)
and the EU Research and Innovation Directorate Generalof a Novel Risk Marker
ithout outcome?
outcomes in a prospective cohort or nested case-cohort/case-cohort study?
lished standard risk markers?
to change recommended therapy?
es, especially when tested in a randomized clinical trial?
ntly to justify the additional costs of testing and treatment?
, Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind
tific statement from the American Heart Association, 2408-16, 2009, with
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representatives presented goals and visions regarding per-
sonalized medicine. Notably, the alignment of these
agencies is encouraging and may provide a framework for
global collaborative efforts. The EU Framework Pro-
gramme for Research and Technological Development
has devoted a great portion of available funding to research
in health initiatives.71 Personalized medicine is one area
identified as a priority for funding research, which would
include the creation of networks among academic institu-
tions, industry, regulatory agencies, patient representatives,
and other stakeholders. Examples include the European
Commission Seventh Framework Programme for Research
(FP7) and projects such as Biostat-CHF (www.biostat-
chf.eu) and Heart Omics in Ageing (HOMAGE).72
To identify bottlenecks in progress and propose solutions
for future activities, a number of workshops were orga-
nized, and a Personalized Medicine Conference was con-
vened in May 2011.73 Challenges identified included: 1)
generating knowledge and developing the right tools; 2)
translation to clinical applications; 3) breaking down bar-
riers and speaking the same language; and 4) economic im-
pact, with a need for studies and standard methodologies.
The ‘‘time for action’’ in personalized medicine comes in
the context of defining a common strategic framework for
research and innovation activities: Horizon 2020.74
The NHLBI vision of the development of personalized
medicine is remarkably similar. The NHLBI Strategic Plan
includes a mandate to develop personalized preventive and
therapeutic regimens for cardiovascular conditions and
lung and blood diseases.75 Funded programs include re-
search initiatives in systems biology, genomics, fundamental
discoveries, and clinical applications. The nongovernmental
Foundation for the National Institutes of Health supports the
Biomarkers Consortium, a public-private partnership with
multiple industry sponsors. The Consortium is designed to
model biomarkers of atherosclerosis in an effort to facilitate
development of new drugs that may have incremental ther-
apeutic benefit in the era of widespread statin use. This type
of a collaborative approach might also be applied in inte-
grating biomarker data in HF. The NHLBI hosted working
groups on personalized medicine and cardiovascular phar-
macogenomics in 2011.76,77 Participants recommended the
inclusion of DNA collections in NHLBI-funded clinical tri-
als, as is being done in the Heart Failure Clinical Research
Network. Finally, dissemination and sharing of existing
data, as is done for genetic data in the National Institutes
of Healthefunded Database of Genotypes and Phenotypes
(dbGaP)78 remain a crucial foundation for advancing our
understanding of the personalized approach.
Conclusion
Research evaluating personalizedmedicine throughmulti-
marker profiling in HF is proceeding, but a number of chal-
lenges remain despite the potential benefits. There are still
questions regarding the level of evidence needed to support
product approval and labeling. Government agencies areencouraging and supportive, and understand the need for in-
novative treatment approaches. High annual mortality, high
morbidity, and heterogeneity of response to treatment under-
score the need for predictability of response in this patient
population. Although biomarker testing is not routinely be-
ing used to guide therapy in HF, we believe this treatment ap-
proach is not too distant. Certainly the data are supportive,
but further research is warranted to strengthen the approach.
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